Physician profile
David Terhune
NPI 1639157308
$16,120.72
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,747 · 2020: $4,149 · 2021: $1,875 · 2022: $1,350.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Great Lakes Medical Services, LLC | $15,986.00 | 2019-2022 | |
| Astellas Pharma US INC | $26.09 | 2019-2021 | |
| Amgen INC. | $20.97 | 2019 | |
| Boston Scientific Corporation | $18.57 | 2019 | |
| Urogen Pharma, INC. | $15.00 | 2021 | |
| Medtronic USA, INC. | $14.23 | 2019 | |
| Dentsply Ih INC. | $14.08 | 2019 | |
| Abbvie INC. | $13.72 | 2019 | |
| Allergan, INC. | $12.06 | 2019 |
Research and ownership
$45,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Terhune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.